文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > Anticoagulation-- improve care quality or use new alternatives
侵权投诉

Anticoagulation-- improve care quality or use new alternatives

Correspondence

2

3

4

Foster S, Vaughan R, Foster W, Califano J. Estimate of the commercial value of underage drinking and adult abusive and dependent drinking to the alcohol industry. Arch Pediatr Adolesc Med 2006; 160: 473–78.Stockwell T, Zhao J, Chikritzhs T, Green eld T. What did you drink yesterday? Public health relevance of a recent recall method used in the 2004 Australian National Drug Strategy Household Survey. Addiction 2008; 103: 919–28.

Casswell S, Thamarangsi T. Reducing the harm from alcohol: call to action. Lancet 2009; 373: 2247–57.

We have the tools and best practices to address them, but we need to ensure that they are applied and implemented.” Dental diseases are not a niche area of health. Only when oral health is incorporated within the chronic disease discourse will sustained progress be possible.

We declare that we have no con icts of interest.

*Habib Benzian, Martin Hobdell, Judith Mackay

habib.benzian@health-bureau.com

The Health Bureau Ltd, Haversham MK19 7DT, UK (HB); Department of Epidemiology and Public Health, University College London, London, UK (MH); and World Lung Foundation, New York, NY, USA (JM)

Putting teeth into chronic diseases

Robert Geneau and colleagues1 high-light that public-health priorities and

political priorities are not necessarily 1 Geneau R, Stuckler D, Stachenko S, et al.

Raising the priority of preventing chronic

aligned. We could not agree more diseases: a political process. Lancet 2010;

376: 1689–98.with their conclusion that the “neglect

2 The Lancet. Oral health: prevention is key.

of chronic diseases is a political, not a Lancet 2009; 373: 1.technical, failure since cost-e ective 3 World Health Organization. Oral health: action

plan for promotion and integrated disease interventions are available”.

prevention. World Health Assembly Resolution

However, the current discussions WHA60/R17 2007. doc.guandang.net

ebwha/pdf_ les/WHA60/A60_16-en.pdf risk falling into the same trap by

(accessed Jan 24, 2011).

neglecting the most prevalent chronic

4 Beaglehole R, Benzian H, Crail J, Mackay J.

disease worldwide—dental decay. The oral health atlas: mapping a neglected

global health issue. Geneva & Brighton: FDI The global e ect of oral diseases

World Dental Education Ltd & Myriad Editions,

on health and health systems (oral 2009.

diseases rank fourth in terms of 5 Petersen PE, Bourgeois D, Ogawa H,

Estupinan-Day S, Ndiaye C. The global burden health-system costs) is largely ignored

of oral diseases and risks to oral health.

or underestimated.2,3Bull World Health Organ 2005; 83:

Anticoagulation-- improve care quality or use new alternatives

661–69.The global epidemic of dental decay a ects more than 90% of the world’s

population: between 40% and 90% Anticoagulation: of 12-year-olds have dental decay and I declare that I have no con icts of interest.improve care quality or its consequences, such as pain, chronic

Joyce H S Youinfection, absenteeism, low quality of use new alternatives?joyceyou@cuhk.edu.hk

life, and e ects on growth, develop-ment, and educational performance. Lars Wallentin and colleagues (Sept 18, School of Pharmacy, Faculty of Medicine, Chinese

University of Hong Kong, Shatin, NT, Hong Kong,

In low-resource countries almost all p 975)1 reanalysed results of the RE-LY SAR Chinadecay remains untreated.4,5trial to assess the interaction between 1 Wallentin L, Yusuf S, Ezekowitz MD, et al.

E cacy and safety of dabigatran compared Stakeholders in global oral health quality of anticoagulation care in each

with warfarin at di erent levels of

have not succeeded in framing the study centre (measured as the centre’s international normalised ratio control for problem in a way that resonates with mean time in therapeutic range stroke prevention in atrial brillation: an

analysis of the RE-LY trial. Lancet. 2010; ments broader public-health agendas. We [cTTR]) and clinical improve

376: 975–83.

are concerned that oral health, once seen with dabigatran compared with 2 Chan FWH, Wong RSM, Lau WH, et al.

Management of Chinese patients on warfarin brillation. All cardio-again, will be neglected in favour of warfarin in atrial

therapy in two models of anticoagulation

other disease entities simply because vascular events and total mortality service—a prospective randomized trial. they have more visible advocacy rates were reduced with dabigatran at Br J Clin Pharmacol 2006; 62: 601–09.

3 Ho LY, Siu CW, Yue WS, et al. Safety and low cTTR sites.campaigns.

e cacy of oral anticoagulation therapy in

Despite the clear evidence for war farin In January, 2007, the WHO Director-Chinese patients with concomitant atrial

brillation and hypertension. J Hum Hypertens General said that “oral diseases are a in the prevention of ischaemic stroke

2010; published online July 1. DOI:10.1038/

brillation, neglected area of international health. for patients with atrial jhh.2010.57.

464

doc.guandang.net Vol 377 February 5, 2011

warfarin underuse is common owing

to the complexity of anticoagulation care. In Hong Kong, the best anticoagulation care was achieved in a pharmacist-managed anticoagulation service (mean TTR 64%), followed by a physician-managed anticoagulation service (59%), a cardiac outpatient service (50%), and routine medical care (42–45%).2–4 However, although it had the highest quality of anticoagulation care, this pharmacist-managed anti-coagulation service is the only one of its kind in Hong Kong. Most health-care systems in China do not have any anticoagulation services at all.

Genotype-guided dosing of war- farin was shown to be potentially cost-e ective in practice sites with low cTTR in a decision analysis,5 consistent with the conclusion of Wallentin and colleagues. Practice sites with low cTTRs should obviously consider new interventions, namely upgrading to an anticoagulation specialty service, and, in the near future, use of warfarin pharmacogenomics to guide dosing and use of new anticoagulants, since these sites are likely to bene t the most with the new inter ven tions. All these interventions have different costs and clinical and operational implications for clinicians and decision makers to consider.

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email